Compare KTB & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | SLNO |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 2.5B |
| IPO Year | N/A | 2014 |
| Metric | KTB | SLNO |
|---|---|---|
| Price | $76.25 | $51.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $96.38 | ★ $110.90 |
| AVG Volume (30 Days) | 550.9K | ★ 1.8M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $2,833,659,000.00 | $98,675,000.00 |
| Revenue This Year | $20.46 | N/A |
| Revenue Next Year | $11.11 | $155.86 |
| P/E Ratio | $19.64 | ★ N/A |
| Revenue Growth | ★ 9.91 | N/A |
| 52 Week Low | $50.00 | $41.50 |
| 52 Week High | $96.80 | $90.32 |
| Indicator | KTB | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 48.33 |
| Support Level | $71.85 | $47.80 |
| Resistance Level | $78.28 | $53.10 |
| Average True Range (ATR) | 2.34 | 2.47 |
| MACD | 0.89 | 1.09 |
| Stochastic Oscillator | 78.58 | 79.48 |
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.